Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eylea in nAMD with limited response to ranibizumab
NCT02309281Phase 4Completed
- Sponsor
- Vista Klinik
- Start
- May 2013
- Primary completion
- May 2014
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
A Phase 4 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Vista Klinik. Started May 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02309281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02309281.